David joined Medicines for Malaria Venture "in 2011. Under his leadership, this not-for-profit research foundation has brought forward five new antimalarial drugs, broadened its malaria-drug pipeline to include nine novel drugs in clinical development.
"Prior to joining MMV, David was a Vice President in the Global Product Strategy Unit at F. Hoffman-La Roche Ltd in Basel, Switzerland, where he served as Pandemic Taskforce Leader. Prior to that he was the Global Franchise Leader for HIV/AIDS at Roche, where he oversaw the successful development and introduction of enfuvirtide, the first HIV fusion inhibitor. He has 20 years of management experience in the healthcare industry spanning across successful leadership of drug development teams; licensing and alliance management; market analytics and business planning; product and disease area management; and interfacing with Governments, NGOs and patient advocacy groups in priority disease areas including HIV/AIDS and pandemic influenza."
- Director, Coalition for Epidemic Preparedness Innovations 
- Director, Roll Back Malaria Partnership